Compare
Jyong Biotech Ltd. vs Abvc Biopharma, Inc. vs Annovis Bio, Inc. vs Incannex Healthcare Inc.
| Latest fiscal year | Jyong Biotech Ltd. MENS | Abvc Biopharma, Inc. ABVC | Annovis Bio, Inc. ANVS | Incannex Healthcare Inc. IXHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | n/a | $296.0K | $0 | $86.0K |
| Revenue growth (YoY) | n/a | -41.9% | n/a | +616.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$4.67M | -$7.91M | -$28.85M | -$46.88M |
| EPS (Diluted) | -$0.06 | -$0.39 | -$1.40 | -$1.35 |
| Operating cash flow | -$3.04M | -$2.99M | -$25.62M | -$12.51M |
| Free cash flow | n/a | n/a | n/a | -$12.52M |
| Cash & equivalents | n/a | $681.5K | $19.53M | $15.04M |
| Total assets | $20.78M | $21.06M | $21.08M | $20.45M |
| Total liabilities | $45.68M | $7.76M | $4.23M | $7.06M |
| Shareholders' equity | -$24.91M | $11.11M | $16.85M | $13.39M |
| Return on year-end equity | n/a | -71.2% | -171.2% | -350.2% |
| Shares outstanding | 76.03M | 25.05M | 27.20M | 194.38M |
Revenue, most recent five fiscal years
| Fiscal year | Jyong Biotech Ltd. | Abvc Biopharma, Inc. | Annovis Bio, Inc. | Incannex Healthcare Inc. |
|---|---|---|---|---|
| Latest | n/a | $296.0K Ended 2025-12-31 | $0 Ended 2025-12-31 | $86.0K Ended 2025-06-30 |
| 1 year earlier | n/a | $509.6K Ended 2024-12-31 | $0 Ended 2024-12-31 | $12.0K Ended 2024-06-30 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | n/a |